Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues

AIDS

Volumn 25, Issue 1, 2011, Pages 73-79

  Martín Carbonero, Luz ^a   Teixeira, Tiago ^a   Poveda, Eva ^a   Plaza, Zulema ^a   Vispo, Eugenia ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

elastometry; HBsAg; hepatitis B; hepatitis delta; HIV; lamivudine; seroconversion; tenofovir

Indexed keywords

EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLEARANCE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SUPERINFECTION; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650307553     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328340fde2     Document Type: Article

References (42)

1. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas D. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
2. Bonacini M, Bzowej N, Louie S, Wohl A. Survival in patients with HIV infection and viral hepatitis B or C. AIDS 2004; 18:2039-2045.
3. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:2117-2125.
4. Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martín-Carbonero L, et al. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. HIV Clin Trials 2006; 7:246-250.
5. Lee T, Nuñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV coinfected patients. HIV Clin Trials 2009; 10:153-159.
6. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999; 30:1302-1306.
7. Soriano V, Rivas P, Nuñez M. Risks and benefits of using anti-retroviral therapyinHIV-infected patients with chronichepatitis B in developing regions. Clin Infect Dis 2008; 47:1486-1489.
8. Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, Vispo E, Casado R, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15:165-172.
9. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteleup E, Haasen M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
10. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measure ment of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
11. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastogra-phy: a prospective study. Gut 2006; 55:403-408.
12. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
13. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, et al. Liver stiffness in the hepatitis B virus carrier: a noninvasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008; 14:6154-6162.
14. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29:242-247.
15. Wang J, Changchien C, Hung C, Eng H, Tung W, Kee K, et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2009; 44:439-446.
16. ChanH, Wong G, Choi P, Chan A, ChimM,YiuK, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16:36-44.
17. Kim S, Kim D, Park J, Lee J, Ahn S, Kim J, et al. How can we enhance the performance of liver stiffness measurement using Fibroscan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010; 44:66-71.
18. Nikolopoulos G, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-1771.
19. Hoffmann C, Seaberg E, Young S, Witt M, D'Acunto K, Phair J, Thio C. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23:1881-1889.
20. Dore G, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24:857-865.
21. Iloeje U, Yang H, Su J, Jen C, You S, Chen C, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load. Gastroenterology 2006; 130:678-686.
22. Chen C, Yang H, Su J, Jen C, You S, Lu S, et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
23. Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
24. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiolo-gical studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354.
25. Gaeta G, Stornaiuolo G, Precone D, Lobello S, Chiaramonte M, Stroffolini T, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multi-center Italian study. J Hepatol 2003; 39:1036-1041.
26. Lin L, Verslype C, van Pelt J, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol 2006; 18:1311-1319.
27. Chu C, Lee S. Hepatitis B/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23:512-520.
28. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420-426.
29. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39:212-219.
30. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-hepatitis B virus international panel. AIDS 2008; 22:1399-1410.
31. Hammer S, Eron J, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
32. DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Dec 2009. http://www.aidsin-fo.nih.gov.
33. EACS guidelines. November 2009. http://www.europeanaid-sclinicalsociety. org.
34. Lok A, McMahon B. Chronic hepatitis B: update. Hepatology 2009; 50:1-36.
35. McMahon B, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-768.
36. Chu Y, Liaw Y. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45:1187-1192.
37. Keefe E, Dieterich D, Han S, Jacobson I, Martin P, Schiff E, Tobias H. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
38. Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, et al. Impact of HAART on the natural history of hepatitis B virus and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624-632.
39. Sheng W, Kao J, Chen P, Huan L, Chang S, Sun H, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45:1221-1229.
40. Sheldon J, Ramos B, Toro C, Ríos P, Martínez-Alarcón J, Bot-tecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008; 13: 97-102.
41. Bodsworth N, Donovan B, Nightingale B. The effect of concurrent HIV infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160:577-582.
42. Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham B, Auperin A, et al. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:759-768.